Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 30, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National Walks to Defeat ALS® and Premier Level National ALS Advocacy Conference Sponsorship as well as Platinum Level Sponsorship for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area. “The ALS Association and The ALS Association Golden West Chapter have been exceptional partners over the many years we’ve worked together in supporting patients, caregivers, and advocates of our ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In honor of ALS Awar
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at JMP Securities from $110.00 to $106.00. They now have a "market outperform" rating on the stock.MarketBeat
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $107.00 to $106.00. They now have an "outperform" rating on the stock.MarketBeat
- Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.MarketBeat
- Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 5/8/24 - Miss
CYTK
Sec Filings
- 5/10/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/8/24 - Form 8-K
- CYTK's page on the SEC website